

Clinical Obesity

in Adults and Children

Fourth Edition

Edited by

Peter G. Kopelman | Ian D. Caterson | William H. Dietz

Associate Editors

Sarah Armstrong | Arianne N. Sweeting | John P.H. Wilding

WILEY Blackwell

Table of Contents

[Cover](#)

[Title Page](#)

[Copyright Page](#)

[List of Contributors](#)

[Preface](#)

[Dedication](#)

[List of Abbreviations](#)

[1 Obesity](#)

[1 Obesity - Introduction](#)

[Obesity as a public health problem](#)

[Lower limits of BMIs in non-Caucasians?](#)

[Morbidity burden starts at much lower BMIs](#)

[Obesity epidemic starts in the early 1980s](#)

[The global epidemic gets underway](#)

[Abdominal obesity](#)

[Different regional societal burdens of obesity with abdominal obesity](#)

[Historical analyses of contributors to obesity](#)

[The burden of obesity](#)

[The economic impact of excess weight gain](#)

[Conclusions](#)

[References](#)

[2 The Epidemiology and Social Determinants of Obesity](#)

[Introduction](#)

[Defining excess body fat](#)

[Adult obesity](#)

[Childhood obesity](#)

[Global obesity](#)

[Social determinants of obesity](#)

[Conclusions](#)

[References](#)

[2 Causes of Obesity](#)

[3 Fetal and Infant Origins of Obesity](#)

[Background](#)

[Assessing obesity in children](#)

[Conceptual frameworks](#)

[Study designs](#)

[Developmental risk factors](#)

[Biology and mechanisms](#)

[Estimating population attributable risks](#)

[Implications for policy and practice](#)

[Acknowledgments](#)

[References](#)

[4 Genes and Obesity](#)

[Introduction](#)

[Historical perspective](#)

[Gene-environment interactions](#)

[Evidence for the heritability of fat mass](#)

[Adoption studies](#)

[Twin studies](#)

[Pleiotropic obesity syndromes](#)

[Prader-Willi syndrome](#)

[Albright hereditary osteodystrophy](#)

[Bardet-Biedl syndrome](#)

[Molecular mechanisms involved in energy homeostasis](#)

[Rodent models of obesity](#)

[Leptin-melanocortin pathway](#)

[Monogenic obesity syndromes affecting the leptin-melanocortin pathway](#)

[Response to leptin therapy](#)

[Leptin receptor deficiency](#)

[POMC deficiency](#)

[Prohormone convertase 1 deficiency](#)

[MC4R deficiency](#)

[Conclusions](#)

[References](#)

[5 Bias, Stigma, and Social Consequences of Obesity](#)

[Social consequences for adults](#)

[Social consequences for youth](#)

[Impact of weight stigma on health](#)

[Interventions to prevent and reduce weight stigma](#)

[Conclusion](#)

[References](#)

[6 Ecology, Protein Leverage, and Public Health](#)

[Introduction](#)

[An ecological view of nutrition](#)

[Human macronutrient regulation](#)

[Human nutritional ecology](#)

[Bringing it all together: complex systems](#)

[Conclusions](#)

References

7 The Living Environment and Physical Activity

From the environment to behaviors to obesity

Physical activity and health

Physical activity and weight gain

Spatial variation in obesity

Measuring attributes of the built environment

Relations between the built environment,
physical activity, and obesity

Research trends

Changes in the urban environment

Conclusion

References

8 Psychobiology of Obesity

Setting the scene

Can obesity be managed through behavior
change?

Complex bio-cultural system of appetite control

The bio-behavioral appetite system: tonic and
episodic processes

The satiety cascade: homeostatic and hedonic
processes

Individual variation in susceptibility to
overconsumption: phenotypes for appetite
control

Satiety responsiveness and the low satiety
phenotype

Sensitivity to food reward

Compensation in response to exercise

Implications for the treatment and prevention of obesity and future directions

Closing comments

References

9 Energy Balance and Body Weight Homeostasis

Introduction

Basic concepts and principles in human energetics

Control of food intake

Autoregulatory adjustments in energy expenditure

Integrating intake and expenditure

References

3 Obesity as a Disease

10 Obesity, Ectopic Fat and Type 2 Diabetes

Introduction

Epidemiology

Not all fat is the same

Metabolically healthy obese and metabolically unhealthy lean

Pathogenesis of visceral and ectopic fat accumulation

Factors affecting body fat distribution

Linking ectopic fat accumulation to diabetes

How can we measure VAT and ectopic fat

Therapy

Conclusion

References

11 Obesity and Dyslipidemia, Importance of Body Fat Distribution

[Introduction](#)

[Limitations to fat storage](#)

[Hyperlipidemia in relation to adiposity](#)

[The dynamics and difference of adipose tissue depot functions in the body in relation to hyperlipidemia](#)

[Associations between plasma lipids and lipoproteins and discrete fat depots](#)

[References](#)

[12 Obesity and Fertility](#)

[Introduction](#)

[References](#)

[13 Metabolic Syndrome and Metabolic Dysfunction-Associated Fatty Liver Disease](#)

[Introduction](#)

[Pathogenesis of MS](#)

[Pathogenesis and clinical implications of MAFLD](#)

[Association between MS and MAFLD](#)

[Pathological link between MAFLD and MS](#)

[Inflammation, linked with MS, is the main determinant in progression from NAFLD to NASH](#)

[Increased inflow of FFAs and de novo hepatic lipogenesis are the main determinants of MAFLD](#)

[Oxidative and ER stresses are involved in the association between MS and MAFLD](#)

[Adiponectin, a critical link between MS and MAFLD](#)

[Role of gut microbiota in the crosstalk between MAFLD and MS](#)

[Association of sarcopenia with MS and MAFLD](#)

[Medications for the treatment of MAFLD/NASH](#)

[Role of SGLT2 inhibitors](#)

[Role of GLP1 receptor agonists](#)

[Conclusions](#)

[References](#)

[14 Cardiovascular Consequences](#)

[Introduction](#)

[Epidemiology](#)

[Risk associations in people with the prevalent disease - obesity paradox or confounding?](#)

[Genetics of obesity and cardiovascular outcomes](#)

[Mechanisms](#)

[Interventions: weight loss benefits in CV medicine](#)

[Timing of weight loss benefits on metabolic versus ASCVD outcomes](#)

[Summary](#)

[References](#)

[15 Obstructive Sleep Apnea](#)

[Sleep-disordered breathing](#)

[Sleep-disordered breathing: epidemiology](#)

[Sleep-disordered breathing: clinical aspects](#)

[Sleep disordered breathing: treatment](#)

[Conclusion](#)

[References](#)

16 Obesity and Cancer

General mechanisms linking obesity and cancer

Colorectal cancer

Breast cancer

Stomach cancer

Liver cancer

Esophageal cancer

Pancreatic cancer

Ovarian cancer

Intentional weight loss

Early life risk factors for cancer

Dietary characteristics

Comprehensive integration of the evidence-base

Disclosure

References

4 Management of Adult Obesity

17 A Practical Approach to Contemporary Obesity Management

Introduction

Obesity

Weight loss

Weight control in the age of SARs-CoV-2 coronavirus (COVID-19)

Aims of obesity treatment

Current obesity treatment options

Where should these interventions be available/delivered?

Summary

Appendix A

References

18 Dietary Management of Obesity

Dietary treatment of obesity

Energy deficit

Energy density

Low-fat diets

Plant-based diets

Mediterranean diets

Low energy diets

Partial meal replacement therapy

Low carbohydrate or higher protein diets

Ketogenic diets

Very low energy (calorie) diets (VLEDs)

Intermittent energy restriction

The less restrictive dieting approach

Ultra-processed food

Sugar sweetened beverages

Basic principles

Nutrition in practice

Portion sizes and eating frequency

Maintenance and/or success

Clinical guidelines

Conclusion

References

19 The Behavioral Treatment of Obesity

Behavioral treatment

Components of behavioral treatment

[Dietary options for weight loss](#)

[Physical activity](#)

[Structure of behavioral treatment](#)

[Short- and long-term weight losses](#)

[Strategies to improve long-term weight losses](#)

[New behavioral approaches](#)

[Implementation and dissemination of behavioral treatment](#)

[Conclusion](#)

[References](#)

[20 Role of Exercise and Physical Activity in Promoting Weight Loss and Weight Loss Maintenance](#)

[Introduction](#)

[Operational definitions](#)

[Relationships between PA levels and body mass](#)

[Relationships between sedentary behavior and body mass](#)

[Energy balance considerations](#)

[Exercise and weight reduction](#)

[Resistance training](#)

[Exercise factors that may influence magnitude of weight loss](#)

[Can walking interventions aid weight loss?](#)

[Using other measures of excess weight to determine the metabolic benefit of exercise](#)

[Biological response to weight loss from any type of intervention](#)

[Evidence for metabolic adaptations to exercise](#)

Heterogeneity in exercise response and the concept of *responders vs. nonresponders*

Use of exercise/PA as a tool to achieve weight loss maintenance (WLM)

Conclusions

References

21 Adjunctive Therapy, Including Pharmacotherapy

Introduction and general principles

Classification of obesity medication

Currently approved drugs

Potential future targets including medications not licensed for use in obesity

The use of anti-obesity drug therapy post-bariatric surgery

Conclusion

References

22 The Management of Obesity

Introduction

The evolution of surgical technique

Overview of outcomes from bariatric procedures

Weight loss outcomes from bariatric surgery

Changes in health after bariatric surgery

Survival after bariatric surgery

The Swedish Obese Subjects (SOS) study

Safety of bariatric surgery

Conclusion

References

23 Weight Loss Maintenance and Weight Cycling

What is weight loss maintenance and how is it defined?

What lifestyle characteristics are associated with weight maintenance success?

Interventions - what works for weight loss maintenance, and when

Relationship between quantity of intentional weight loss and weight maintenance success

Weight maintenance in those postbariatric surgery

Weight loss maintenance post pharmacologically assisted weight loss

Weight maintenance using Intermittent weight loss LELD approaches

Clinical and commercial approaches for weight loss maintenance

Conclusion

References

24 Training and Medical Systems for Obesity Care

The current state of obesity knowledge and care

Medical education

Provider training and competencies

Obesity medicine education collaborative competencies

Medical licensure

Obesity medicine as a specialty

Systems of care for obesity

Summary

References

5 Childhood Obesity

25 The Prevention of Childhood Obesity

Introduction

Obesity prevention in clinical settings

Early childhood

Schools

Behavior change interventions in communities

Policy interventions in communities

Country-level Initiatives

Sugary drink taxes

Novel approaches to obesity prevention

Criteria for the selection of prevention strategies

Summary

References

26 Consequences of Childhood and Adolescent Obesity

Seeing the child and youth in context

Comparing the consequences of obesity, and obesity as a causal factor of chronic health conditions

Conclusion

References

27 The Treatment of Childhood and Adolescent Obesity

Introduction

Approach to the child with obesity

Treatment overview

Treating obesity as a chronic disease

[Behavioral interventions](#)

[Motivational interviewing and primary care counseling to modify lifestyle behaviors](#)

[Comprehensive multidisciplinary obesity treatment](#)

[Specific dietary modifications](#)

[Pharmacotherapy](#)

[Information systems](#)

[Conclusions](#)

[References](#)

[6 Policy Approaches](#)

[28 Policy Approaches to Obesity Prevention](#)

[Early interest in obesity policy: the 1970s and 1980s](#)

[Ecological determinants of obesity: the 1990s and early 2000s](#)

[Global development and systems approach: the early 2000s](#)

[Targets and “best buys” in the early 2010s](#)

[From best buys to regulating commerce: the later 2010s](#)

[A sustainable political economy of health: the 2020s](#)

[The political economy of obesity: building a sustainable response](#)

[Conclusion](#)

[References](#)

[29 The Double Burden of Malnutrition](#)

[Introduction](#)

[Scope of the problem and prevalence](#)

[Dynamics of the double burden](#)

[Early childhood development amidst double burden malnutrition](#)

[Conclusion](#)

[Acknowledgments](#)

[References](#)

[30 Taxes, Subsidies, and Policies](#)

[Introduction](#)

[Food environments and dietary determinants](#)

[Impact on dietary patterns and health](#)

[Breastfeeding practices](#)

[Interventions in healthcare settings](#)

[Marketing restrictions for unhealthy products](#)

[References](#)

[31 The Global Syndemic of Obesity, Undernutrition, and Climate Change](#)

[Background](#)

[Malnutrition in all its forms](#)

[The Global Syndemic](#)

[Policy inertia](#)

[Systems thinking approach to the Global Syndemic](#)

[Double- and triple-duty actions](#)

[Applying systems approaches - cities](#)

[Applying systems approaches - communities](#)

[References](#)

[Index](#)

[End User License Agreement](#)

List of Tables

Chapter 2

[Table 2.1 Select sources of data on trends in obesity for the United States ...](#)

[Table 2.2 Cut-offs for defining excess body fat using anthropometric measure...](#)

[Table 2.3 Prevalence of obesity in adults by region and sex, 2016](#)

Chapter 4

[Table 4.1 Pleiotropic genetic obesity syndromes](#)

[Table 4.2 Monogenic obesity syndromes affecting the leptin-melanocortin path...](#)

Chapter 7

[Table 7.1 Obesogenic built environment features as assessed by the Spotlight...](#)

[Table 7.2 Association of built environment features related to physical acti...](#)

Chapter 8

[Table 8.1 Variables identified in the obesity systems map organized by doma...](#)

Chapter 10

[Table 10.1 Adipokines, the effects on their target organs and the net effect...](#)

[Table 10.2 IDF consensus on waist circumference cut-off for different ethnic...](#)

[Table 10.3 Clinically usable parameters to estimate VAT.](#)

Chapter 12

[Table 12.1 Maternal and offspring complications of obesity.](#)

Chapter 13

[Table 13.1 Studies of the independent association of MAFLD, including previo...](#)

[Table 13.2 Efficacy of sodium-glucose cotransporter 2 \(SGLT2\) inhibitors in ...](#)

[Table 13.3 Efficacy of glucagon-like peptide 1 \(GLP1\) receptor agonists in p...](#)

Chapter 14

[Table 14.1 Risk pathways that may explain links between excess adiposity and...](#)

[Table 14.2 A summary of key pieces of evidence from epidemiology, genetics, ...](#)

Chapter 15

[Table 15.1 Definitions in sleep-disordered breathing](#)

[Table 15.2 Sleepiness in the patients with obesity.](#)

[Table 15.3 Symptoms of sleep-disordered breathing](#)

Chapter 17

[Table 17.1 Classification of overweight and obesity in adults and the cut-of...](#)

[Table 17.2 Benefits of 5-10% weight loss \(Ref\).](#)

[Table 17.3 Goals of obesity management](#)

[Table 17.4 Treatment modalities for obesity.](#)

[Table 17.5 Practical approach to obesity treatment - clinical assessment and...](#)

[Table 17.6 Essential elements for the management of overweight and obesity.](#)

[Table 17.A.1 Clinical history of a person with obesity – key points](#)

[Table 17.A.2 Drug treatment which may be associated with weight gain](#)

[Table 17.A.3 Measures that can be taken at home](#)

Chapter 18

[Table 18.1 Recommendations and clinical guidelines for the management of obe...](#)

Chapter 19

[Table 19.1 FDA-approved anti-obesity medications for chronic weight managemen...](#)

Chapter 20

[Table 20.1 Studies showing the impact of exercise duration on weight loss re...](#)

[Table 20.2 Studies showing the impact of exercise EE on weight loss response...](#)

Chapter 21

[Table 21.1 Principles of prescribing in obesity \[12,17\].](#)

Chapter 22

[Table 22.1 Results from a systematic review of reports of bariatric procedur...](#)

[Table 22.2 Studies of survival benefits of weight loss surgery](#)

Chapter 23

[Table 23.1 Commonly reported weight loss maintenance definitions](#)

[Table 23.2 Characteristics of successful weight loss maintainers](#)

Chapter 24

[Table 24.1 Provider training organizations and education organizations invol...](#)

[Table 24.2 Obesity Medicine Education Collaborative core domains and associa...](#)

Chapter 27

[Table 27.1 Evidence-based behaviors](#)

[Table 27.2 Likely but unproven benefit, low harm behaviors](#)

[Table 27.3 Treatment intensity and BMI reduction in randomized controlled tr...](#)

[Table 27.4 Bariatric surgery eligibility critiera \[88\].](#)

Chapter 28

[Table 28.1 Interventions recommended by WHO in 2013](#)

Chapter 30

[Table 30.1 Types of taxes](#)

[Table 30.2 The case of Mexico](#)

Chapter 31

[Table 31.1 Criteria for a whole of systems approach, related systems dynamic...](#)

List of Illustrations

Chapter 1

[Figure 1.1 Obesity prevalences in different regions of the world. Data for m...](#)

[Figure 1.2 The prevalences of obesity in men and women in cohorts with over ...](#)

[Figure 1.3 The relationship between the prevalences of obesity and diabetes ...](#)

[Figure 1.4 An illustration of the principal factors leading to the obesity e...](#)

[Figure 1.5 The global burden of disease assessed in terms of disability-adju...](#)

[Figure 1.6 The McKinsey Global Institute's economic analysis of the social b...](#)

Chapter 2

[Figure 2.1 Prevalence of obesity \(body mass index \$\geq 30\$ kg/m²\) among adults in...](#)

[Figure 2.2 World map of the prevalence of adult obesity \(age 20+ years\) in 2...](#)

[Figure 2.3 World map of the prevalence of childhood obesity in girls \(a\) and...](#)

[Figure 2.4 World map of the prevalence of childhood obesity in girls \(a\) and...](#)

Chapter 3

[Figure 3.1 Lifecourse view of noncommunicable disease risk.](#)

[Figure 3.2 Associations of maternal pre-pregnancy BMI and gestational weight...](#)

[Figure 3.3 Association of Mediterranean diet score in pregnancy with child B...](#)

[Figure 3.4 Association of maternal number of cigarettes smoked per day and r...](#)

Chapter 4

[Figure 4.1 Clinical response to leptin therapy in congenital leptin deficien...](#)

[Figure 4.2 Changes in energy intake and expenditure in two children with con...](#)

[Figure 4.3 Leptin therapy is associated with pulsatile gonadotropin secretio...](#)

[Figure 4.4 Hypothalamic pathways regulating body weight.](#)

Chapter 5

[Figure 5.1 Ecological model of weight stigma.](#)

Chapter 6

[Figure 6.1 Basic concepts in the Nutritional Geometry framework. \(a\) Dietary...](#)

[Figure 6.2 Homeostatic regulation of dietary balance by insects. \(a\) Self-se...](#)

[Figure 6.3 Regulatory responses by free-ranging Peruvian spider monkeys \(Ate...](#)

[Figure 6.4 Dietary macronutrient regulation in humans. \(a\) Data from the FAO...](#)

[Figure 6.5 Response of human appetite systems to variation in dietary macron...](#)

[Figure 6.6 Effect on protein leverage of increased protein requirements rela...](#)

[Figure 6.7 Relationship between ultra-processed food consumption and protein...](#)

Chapter 7

[Figure 7.1 General framework of living environments, energy-related behavior...](#)

[Figure 7.2 Difference between self-defined neighborhood and buffer around re...](#)

Chapter 8

[Figure 8.1 The obesity systems map \[20\]. Content is available under the Open...](#)

[Figure 8.2 illustrates how tonic and episodic influences interact. Tonic exc...](#)

[Figure 8.3 Satiety cascade \[26\] depicts the interplay between the homeostati...](#)

[Figure 8.4 Model to explain overconsumption with highly palatable food \[27\]....](#)

Chapter 9

[Figure 9.1 Principles of energy balance within a schematic framework that de...](#)

[Figure 9.2 Contribution of organ/tissues to basal metabolic rate \(BMR\) of a ...](#)

[Figure 9.3 Components of energy expenditure contributing to voluntary and in...](#)

[Figure 9.4 Hypothalamic circuits implicated in the control of food intake de...](#)

[Figure 9.5 Neuropeptides implicated in coordinated effects on both energy in...](#)

[Figure 9.6 Sympathetic nervous system \(SNS\) activity in various organs/tissu...](#)

[Figure 9.7 Integrating energy intake and energy expenditure in an overview o...](#)

Chapter 10

[Figure 10.1 Schematic representation of the mechanisms linking adipokines an...](#)

Chapter 11

[Figure 11.1 The human white adipose tissue fat storing compartments are made...](#)

Chapter 13

[Figure 13.1 Role of inflammation and oxidative stress in the pathogenesis of...](#)

[Figure 13.2 Contributing factors linking MAFLD with MS. ER, endoplasmic reti...](#)

Chapter 14

[Figure 14.1 Hazard ratios \(HRs\) for CHD and ischemic stroke across quantiles...](#)

[Figure 14.2 Associations between body mass index \(kg/m²\), HbA1c, and the ris...](#)

[Figure 14.3 Associations of genetically predicted 1 kg/m² increase in \(a\) bo...](#)

[Figure 14.4 Redefining pathways to heart failure and renal disease in patien...](#)

[Figure 14.5 Cumulative incidence rates during 9 years of follow-up. \(a\) Macr...](#)

[Figure 14.6 This figure summarises the wide range of evidence linking obesit...](#)

Chapter 15

[Figure 15.1 5-minute tracing of a patient with typical severe obstructive sl...](#)

[Figure 15.2 Two-hour oximetry recording, with transcutaneous \(tc\) CO₂ monito...](#)

[Figure 15.3 Obesity \(measured by BMI kg/m²\) is an important predictor of OSA...](#)

[Figure 15.4 \(a\) One-hour oximetry recording during sleep in a patient with s...](#)

[Figure 15.5 Five-minute tracing of a patient with typical severe obstructive...](#)

[Figure 15.6 Efficacy of nasal ventilation in a patient with OHS. Recordings ...](#)

Chapter 16

[Figure 16.1 Cancers associated with overweight and obesity.](#)

[Figure 16.2 Incidence and mortality from specific cancer sites in males and ...](#)

[Figure 16.3 Body mass index and colorectal cancer, nonlinear dose-response....](#)

Chapter 18

[Figure 18.1 A meta-analysis of weight loss in 48 ad libitum low-fat diet int...](#)

[Figure 18.2 Weight change over 4 year periods according to quintiles of chan...](#)

[Figure 18.3 Weight loss patterns for those on a 5-6 MJ \(1200-1500 kcal\) diet...](#)

[Figure 18.4 Mean weight loss over 12 months of either traditional prescripti...](#)

Chapter 19

[Figure 19.1 Example of a behavioral chain. Each chain represents a process t...](#)

[Figure 19.2 Typical visit flow for an individual patient visit.](#)

Chapter 20

[Figure 20.1 Changes in body weight with a variety of weight-loss interventio...](#)

[Figure 20.2 Physiological adaptations to weight loss. \(a\) A positive "energy...](#)

[Figure 20.3 Relationship between EI and PA level. \(a\) The expected physiolog...](#)

[Figure 20.4 EE plateaus with time \(seen here from week 8 of a half marathon ...](#)

[Figure 20.5 Body weight and calorie intake across multiple PA levels in a st...](#)

[Figure 20.6 \(a\) Relationship between body weight status and the calories req...](#)

Chapter 21

[Figure 21.1 Potential sites of action with examples of drug treatments for o...](#)

[Figure 21.2 Currently approved drugs.](#)

Chapter 22

[Figure 22.1 Jejunioileal bypass.](#)

[Figure 22.2 Roux-en-Y gastric bypass. DNA Illustrations/Science Source.](#)

[Figure 22.3 Vertical banded gastroplasty.](#)

[Figure 22.4 Biliopancreatic diversion.](#)

[Figure 22.5 Biliopancreatic diversion with duodenal switch.](#)

[Figure 22.6 Laparoscopic adjustable gastric band.](#)

[Figure 22.7 Vertical sleeve gastrectomy.](#)

Chapter 23

[Figure 23.1 Weight loss maintenance in self-directed, interactive technology...](#)

[Figure 23.2 Weight regain in 24 month STOP REGAIN study.](#)

Chapter 24

[Figure 24.1 Framework for integrated clinical and community systems of care....](#)

Chapter 25

[Figure 25.1 The social-ecological model emphasizing that institutional, comm...](#)

[Figure 25.2 The Kumanyika Equity-oriented Obesity Prevention Framework. Most...](#)

[Figure 25.3 The Chilean front-of-pack warning labels showing foods high in c...](#)

Chapter 26

[Figure 26.1 Acanthosis nigricans with excrescence on left lateral neck.](#)

[Figure 26.2 Clinical examination of the child/adolescent with obesity, with ...](#)

[Figure 26.3 Accurate height measurement of a child using a stadiometer.](#)

Chapter 27

[Figure 27.1 Different options and settings for the treatment of childhood ob...](#)

Chapter 28

[Figure 28.1 The IOTF Causal Web 1999.](#)

[Figure 28.2 Determinants of nutrition security, WHO-Europe 2002.](#)

[Figure 28.3 Foresight Obesity Systems Map 2007.](#)

[Figure 28.4 UNICEF systems-based schema showing examples of systems influenc...](#)

Chapter 29

[Figure 29.1 Social determinants of health.](#)

Chapter 30

[Figure 30.1 The Innocenti Framework on Food Systems for Children and Adolesc...](#)

[Figure 30.2 The Drivers of Global Syndemic Framework \[3\].](#)

[Figure 30.3 Pathways for the effect of fiscal policy interventions.](#)

Chapter 31

[Figure 31.1 The burden of malnutrition in all its forms.](#)

[Figure 31.2 The Systems Outcomes Framework.](#)

[Figure 31.3 The general relationship between model sophistication and system...](#)

[Figure 31.4 Examples of triple-duty actions.](#)

[Figure 31.5 Causal Loop Diagram \(systems map\) from a WHOSTOPS community.](#)

Clinical Obesity in Adults and Children

FOURTH EDITION

EDITED BY

Peter G. Kopelman, MD, DSC, FRCP, FFPH

Professor of Medicine University of London
London, UK

Ian D. Caterson, AM, MBBS, BSC(MED), PHD, FRACP

Boden Initiative, Charles Perkins Centre and
Boden Professor of Human Nutrition, School of Life and
Environmental Sciences, University of Sydney
Sydney, New South Wales, Australia

William H. Dietz, MD, PHD

Chair, Sumner M. Redstone Global Center for Prevention
and Wellness
Milken Institute School of Public Health
George Washington University
Washington, DC, USA

WITH ASSOCIATE EDITORS

Sarah Armstrong, MD

Professor of Pediatrics and Population Health Sciences
Duke University

Durham, NC, USA

Arianne N. Sweeting, MBBS, BSC, GRADDIP HL, PHD, FRACP

Staff Specialist Endocrinologist
Department of Endocrinology, Royal Prince Alfred Hospital
Boden Initiative, Charles Perkins Centre, University of
Sydney
Sydney, New South Wales, Australia

John P.H. Wilding, DM, FRCP

Professor of Medicine & Honorary Consultant Physician
Department of Cardiovascular and Metabolic Medicine
Institute of Life Course and Medical Sciences
University of Liverpool
Aintree University Hospital Liverpool, UK

WILEY Blackwell